This is an early clinical milestone with no efficacy data yet. The FDA registration pathway for Alpha DaRT in this indication remains unclear. Monitor for initial ORR data from ADMIRE and any updates from the ReSTART trial. The company has a $1.1B market cap with no revenue, so clinical progress is the primary driver.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 15 $12.46entry
- T+1 · 4mo ago −4.65%α −4.11% · $11.88
- T+5 · 4mo ago +4.41%α +5.39% · $13.01
- T+20 · 3mo ago +11.32%α +8.97% · $13.87
- T+60 · 6w ago +12.36%α +9.83% · $14.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced the successful treatment of the first patient in its ADMIRE study, evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). The study targets a high-need population with limited treatment options and builds on momentum from the recently completed ReSTART pivotal trial. This is an early clinical milestone with no efficacy data reported.
Key Facts
- First patient treated in ADMIRE study at Banner MD Anderson Cancer Center
- ADMIRE is a prospective, single-arm study enrolling up to 28 immunocompromised patients with recurrent cSCC
- Primary endpoint: objective response rate (ORR) per RECIST v1.1; secondary endpoints include PFS, OS, and local control over 12 months
- ReSTART pivotal trial for recurrent cSCC recently completed patient enrollment
- Immunocompromised patients face 65- to 100-fold higher incidence of cSCC (organ transplant recipients)
Financial Impact
Clinical milestone; no revenue or financial data provided in the filing.
Risk Factors
- Clinical trial failure risk, no efficacy data from ADMIRE reported yet
- Small sample size (up to 28 patients) limits statistical power
- Regulatory approval for Alpha DaRT in this indication is uncertain and likely years away
- Company is pre-revenue with significant operating losses (per 20-F risk factors)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-078138 |
| Document: ea0297988-6k_alpha.htm | 0001213900-26-078138 |
| Document: 0001213900-26-078138-index-headers.html | 0001213900-26-078138 |
| Document: 0001213900-26-078138-index.html | 0001213900-26-078138 |
| Document: 0001213900-26-078138.txt | 0001213900-26-078138 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers